Predict your next investment

Venture Capital
adventls.com

See what CB Insights has to offer

Investments

162

Portfolio Exits

43

Funds

13

About Advent Life Sciences

Advent Life Sciences is one of Europe's leading venture teams investing in life sciences businesses. We are a deliberately small, and highly focused team of senior individuals, with long-standing track records of entrepreneurial and investment success across the UK, Europe and the USA. Advent invests predominantly in early and mid-stage life sciences companies. The firm seeks to back truly innovative companies that have a first-in-class or best-in-class approach and who are looking for a well-connected partner on the road to success.

Advent Life Sciences Headquarter Location

158-160 North Gower Street

London, England, NW1 2ND,

United Kingdom

+44 (0)20 7932 2100

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Advent Life Sciences News

AviadoBioTM Raises $80 million in Series A Financing to Advance Neurodegenerative Gene Therapy Platform

Dec 3, 2021

Advance Neurodegenerative Gene Therapy Platform Series A led by New Enterprise Associates (NEA) and co-led by Monograph Capital follows seeding by Advent Life Sciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation - JJDC, Inc. (JJDC), and LifeArc AviadoBio’s unique platform combines next-generation gene therapy design with deep neuroscience expertise and a novel neuroanatomy-led approach to drug delivery Co-founded by leading neurologist and neuroscientist Professor Christopher Shaw, molecular neurobiologist Dr Youn Bok Lee and vector biologist Dr Do Young Lee from King’s College London and the UK Dementia Research Institute Lisa Deschamps appointed Chief Executive Officer, bringing 25 years of industry and extensive gene therapy experience London, UK, December 2, 2021 — AviadoBio Ltd, a pioneering gene therapy company focused on developing and delivering transformative medicines for people living with neurodegenerative disorders, announced today the successful completion of an $80 million (£58.6 million) Series A financing round, following an initial $16.5 million (£12 million) seed financing. The funds will be used to advance AviadoBio’s lead program in frontotemporal dementia (FTD) into the clinic, progress its preclinical assets, including for amyotrophic lateral sclerosis (ALS), whilst continuing to expand its industry-leading team. The financing was led by New Enterprise Associates (NEA) and co-led by Monograph Capital, with participation from LSP, as well as seed investors Advent Life Sciences, Dementia Discovery Fund (DDF), F-Prime Capital, JJDC and medical research charity LifeArc. AviadoBio’s technology was developed in the laboratory of Christopher Shaw, Professor of Neurology and Neurogenetics at King’s College London’s Institute of Psychiatry, Psychology & Neuroscience, with the support of the UK Dementia Research Institute, the My Name’5 Doddie Foundation and the Van Geest Foundation and, incubated by F-Prime Capital and JJDC. “Whilst neurodegenerative conditions are focal at onset, the pathology eventually spreads throughout the nervous system. We have seen that modifying gene expression can be curative, but achieving widespread distribution is the greatest challenge. We have shown that precision micro dosing to neural networks will deliver broad CNS expression, providing safe and effective treatments,” said Prof. Christopher Shaw, Co-founder and Chief Scientific and Clinical Advisor of AviadoBio. “We are directly exploiting insights into the causes of diseases to design therapies that have the potential to cure patients for whom there are no effective treatments. I believe that AviadoBio has the potential to move neurodegeneration from palliation to prevention.” Shaw added: “AviadoBio’s unique platform combines next-generation gene therapy design with deep neuroscience expertise and a novel neuroanatomy-led approach to drug delivery. Precision micro dosing achieves extensive gene expression throughout the nervous system, maximizing the therapeutic potential for patients living with devastating neurological diseases.” The Company is led by recently appointed Chief Executive Officer and Board member Lisa Deschamps, former Senior Vice President and Chief Business Officer at Novartis Gene Therapies. Lisa brings more than 25 years of biopharma experience including leading the global neuroscience business of Novartis and the worldwide commercialization of its gene therapy for spinal muscular atrophy. “I am excited about the promise we can bring to people living with neurodegenerative disease, where a significant unmet medical need remains with only symptomatic therapies currently available. Our differentiated approach has the potential to transform the treatment landscape and we have the opportunity with our group of experienced investors, our advisors and founders, to change the lives of people living with these debilitating conditions,” said Lisa Deschamps, Chief Executive Officer. “The expansion of our team and investor syndicate, positions AviadoBio to make this mission a reality while advancing the field.” As part of the Series A financing, Matt McAviney, Partner at NEA and Tim Funnell, Partner at Monograph Capital have been appointed to the Company’s Board of Directors. They are joined by Amber Salzman and Prof. Philip Scheltens as an independent Board Director and a Board Observer for LSP, respectively. Amber has been a pioneering entrepreneur in leading companies and not-for-profit organizations focused on gene therapies and rare diseases for more than 20 years, while Prof. Sheltens is a world-renowned dementia scientist and thought leader. “Traditionally, there have been very few options to combat the devastating course of neurodegenerative disorders,” said Matt McAviney, Partner, NEA and AviadoBio Board member. “AviadoBio’s gene therapy platform introduces a revolutionary approach, supported by world-renowned neuroscience expertise and strong preclinical data. The Company is poised to make a meaningful impact, and we are thrilled to partner with the team to introduce a new portfolio of treatments to patients suffering from a range of debilitating diseases.” About AviadoBio At AviadoBio our mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute, co-founded by Prof. Christopher Shaw, Dr. Youn Bok Lee and Dr. Do Young Lee, with support from leading life science investors and Dr. Jonathan Jones and Dr. Graeme Fielder, as the Company’s founding management team. AviadoBio is building world-class capabilities to discover, develop, manufacture and commercialize gene therapy products. For more information, please visit www.aviadobio.com and follow us at Twitter @AviadoBio and LinkedIn AviadoBio. Contact:

Advent Life Sciences Investments

162 Investments

Advent Life Sciences has made 162 investments. Their latest investment was in Artax Biopharma as part of their Series C on January 1, 2022.

CBI Logo

Advent Life Sciences Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/3/2022

Series C

Artax Biopharma

$12.69M

No

1

12/2/2021

Series A

AviadoBio

$80M

No

6

12/1/2021

Seed VC

AviadoBio

$16.5M

Yes

3

7/7/2021

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

3/22/2021

Series E

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/3/2022

12/2/2021

12/1/2021

7/7/2021

3/22/2021

Round

Series C

Series A

Seed VC

Series B - II

Series E

Company

Artax Biopharma

AviadoBio

AviadoBio

Subscribe to see more

Subscribe to see more

Amount

$12.69M

$80M

$16.5M

$99M

$99M

New?

No

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

6

3

10

10

Advent Life Sciences Portfolio Exits

43 Portfolio Exits

Advent Life Sciences has 43 portfolio exits. Their latest portfolio exit was Aura Biosciences on October 29, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/29/2021

IPO

$99M

1

4/1/2021

Acquired

3

8/11/2020

Acquired

$99M

10

8/6/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

3/13/2019

Reverse Merger

Subscribe to see more

Subscribe to see more

10

Date

10/29/2021

4/1/2021

8/11/2020

8/6/2020

3/13/2019

Exit

IPO

Acquired

Acquired

IPO

Reverse Merger

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

3

10

10

10

Advent Life Sciences Acquisitions

2 Acquisitions

Advent Life Sciences acquired 2 companies. Their latest acquisition was Reqio on January 29, 2001.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/29/2001

Series C

$99M

$6.27M

Leveraged Buyout

1

11/28/1998

Series B

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

1/29/2001

11/28/1998

Investment Stage

Series C

Series B

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

$6.27M

$99M

Note

Leveraged Buyout

Subscribe to see more

Sources

1

10

Advent Life Sciences Fund History

13 Fund Histories

Advent Life Sciences has 13 funds, including Advent Life Sciences Fund III.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/6/2019

Advent Life Sciences Fund III

Multi-Stage Venture Capital

Open

$24.8M

2

10/28/2014

Advent Life Sciences Fund II

Multi-Stage Venture Capital

Closed

$235M

1

11/24/2010

Advent Venture Life Sciences Fund V LP

Multi-Stage Venture Capital

Closed

$125M

1

12/17/2004

Advent Private Equity Fund IV LP

Subscribe to see more

Subscribe to see more

$99M

10

2/9/2001

Advent Private Equity Fund III LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

12/6/2019

10/28/2014

11/24/2010

12/17/2004

2/9/2001

Fund

Advent Life Sciences Fund III

Advent Life Sciences Fund II

Advent Venture Life Sciences Fund V LP

Advent Private Equity Fund IV LP

Advent Private Equity Fund III LP

Fund Type

Multi-Stage Venture Capital

Multi-Stage Venture Capital

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Open

Closed

Closed

Subscribe to see more

Subscribe to see more

Amount

$24.8M

$235M

$125M

$99M

$99M

Sources

2

1

1

10

10

Advent Life Sciences Team

13 Team Members

Advent Life Sciences has 13 team members, including current General Partner, Kaasim Mahmood.

Name

Work History

Title

Status

Kaasim Mahmood

General Partner

Current

Shahzad Malik

General Partner

Current

Rajesh Bhikhu Parekh

General Partner

Current

Raj Parekh

General Partner

Current

Dale R. Pfost

General Partner

Current

Name

Kaasim Mahmood

Shahzad Malik

Rajesh Bhikhu Parekh

Raj Parekh

Dale R. Pfost

Work History

Title

General Partner

General Partner

General Partner

General Partner

General Partner

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.